AngioDynamics (NASDAQ:ANGO) Rating Reiterated by HC Wainwright

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $14.00 target price on the medical instruments supplier’s stock. HC Wainwright’s target price indicates a potential upside of 85.68% from the stock’s current price.

Separately, Canaccord Genuity Group dropped their target price on AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and an average target price of $12.25.

AngioDynamics Trading Down 2.1 %

Shares of ANGO stock opened at $7.54 on Friday. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $8.25. The stock has a market cap of $302.01 million, a P/E ratio of -1.56 and a beta of 0.65. The stock has a 50 day moving average of $7.45 and a 200 day moving average of $6.51.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.11. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The firm had revenue of $71.00 million during the quarter, compared to analyst estimates of $70.86 million. During the same period in the previous year, the firm earned $0.02 EPS. The business’s quarterly revenue was down 22.1% on a year-over-year basis. On average, research analysts predict that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Institutional Trading of AngioDynamics

Several institutional investors have recently modified their holdings of ANGO. Quest Partners LLC purchased a new position in AngioDynamics in the 4th quarter valued at about $69,000. RPO LLC purchased a new position in shares of AngioDynamics in the fourth quarter valued at approximately $83,000. Armistice Capital LLC acquired a new stake in shares of AngioDynamics in the fourth quarter worth approximately $6,272,000. Aristides Capital LLC purchased a new stake in shares of AngioDynamics during the fourth quarter worth approximately $244,000. Finally, ADAR1 Capital Management LLC acquired a new position in AngioDynamics in the 4th quarter valued at $1,042,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.